Thanks for posting. IPIX reviews large potential m
Post# of 72440
(Total Views: 464)
Posted On: 04/09/2019 1:51:34 PM
Re: Commando911 #54886
Thanks for posting. IPIX reviews large potential market fot Brilacidin OM as well as its inherent advantages as a topical treatment.
" Given that Brilacidin is administered as a convenient and patient-friendly oral rinse (swish and spit, 3x daily), we believe that our market penetration could realistically approach 80 percent within the first three years following market introduction. This would translate into a targeted 120,000 treated HNC patients in the U.S. and Europe per year according to the anticipated label indication. Moreover, following regulatory approval in HNC, we would anticipate the potential to expand the label to capture a broadened market—patients experiencing OM across various cancer indications, estimated to include as many as 650,000 people annually (25% to 60% of all cancer patients receiving chemotherapy experience OM).
We believe most other competitor products in development, with less patient-friendly modes of delivery (e.g., IV), would be less able to reach this broader OM market. An additional factor that should help to expedite market adoption of Brilacidin oral rinse includes the potential to avoid incremental inpatient costs incurred in those SOM patients requiring hospitalization, estimated to be between $18,000 and $25,000 per incident. Private and government payers would thus be incentivized to adopt preventative treatment due to large potential cost-savings. We anticipate being able to price Brilacidin at $5,000 to $10,000 per full course of treatment based on the large unmet need as well based on initial pricing for the only other OM drug ever approved (Palifermin, hematopoietic stem cell transplantation, HSCT). Based on our preliminary estimates, the total Brilacidin oral rinse market opportunity annually in the U.S. and Europe would be approximately $600 million to $1.2 billion."
For additional insight into the Brilacidin market opportunity for oral mucositis, refer to additional Company blog posts, linked below:
http://www.ipharminc.com/new-blog/2017/10/17/...-mucositis
http://www.ipharminc.com/new-blog/2018/5/4/br...pportunity
http://www.ipharminc.com/new-blog/2017/12/11/...tis-market
http://www.ipharminc.com/new-blog/2017/8/7/br...-mucositis
" Given that Brilacidin is administered as a convenient and patient-friendly oral rinse (swish and spit, 3x daily), we believe that our market penetration could realistically approach 80 percent within the first three years following market introduction. This would translate into a targeted 120,000 treated HNC patients in the U.S. and Europe per year according to the anticipated label indication. Moreover, following regulatory approval in HNC, we would anticipate the potential to expand the label to capture a broadened market—patients experiencing OM across various cancer indications, estimated to include as many as 650,000 people annually (25% to 60% of all cancer patients receiving chemotherapy experience OM).
We believe most other competitor products in development, with less patient-friendly modes of delivery (e.g., IV), would be less able to reach this broader OM market. An additional factor that should help to expedite market adoption of Brilacidin oral rinse includes the potential to avoid incremental inpatient costs incurred in those SOM patients requiring hospitalization, estimated to be between $18,000 and $25,000 per incident. Private and government payers would thus be incentivized to adopt preventative treatment due to large potential cost-savings. We anticipate being able to price Brilacidin at $5,000 to $10,000 per full course of treatment based on the large unmet need as well based on initial pricing for the only other OM drug ever approved (Palifermin, hematopoietic stem cell transplantation, HSCT). Based on our preliminary estimates, the total Brilacidin oral rinse market opportunity annually in the U.S. and Europe would be approximately $600 million to $1.2 billion."
For additional insight into the Brilacidin market opportunity for oral mucositis, refer to additional Company blog posts, linked below:
http://www.ipharminc.com/new-blog/2017/10/17/...-mucositis
http://www.ipharminc.com/new-blog/2018/5/4/br...pportunity
http://www.ipharminc.com/new-blog/2017/12/11/...tis-market
http://www.ipharminc.com/new-blog/2017/8/7/br...-mucositis
(1)
(0)Innovation Pharmaceuticals Inc (IPIX) Stock Research Links
Scroll down for more posts ▼